1. In Vivo
  2. >>Deal-Making

Medtechs Ready To Take Creative Approach To Deal-Making With An Eye On Start-Ups

 
• By Ashley Yeo

Ground-breaking M&A deals were largely absent from medtech industry schedules in 2018 – Boston’s BTG deal aside – but that does not mean consolidation of the medtech industry is slowing down. M&A deal numbers have been steady of late, even if aggregate deal value has declined in recent years. Digital transformation is a catalyst for a growing number of sector-transforming transactions.

Anyone supposing that global medtech deals have hit the buffers would have been otherwise enlightened at the LSX World Congress, in London, in February 2019. True, Brexit might see confidence take a short-term dip, health systems are fighting for budget and using their reimbursement spends ever-more-carefully, and the forthcoming Medical Device Regulation is painting a somewhat forbidding picture for would-be start-ups up and device innovators in the EU.

But a high-level panel debate on the current climate for adding growth externally put to bed the notion that M&A...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Deals Shaping The Industry, May 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By Deanna Kamienski and Maureen Riordan

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By Ashley Yeo

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 
• By Sushmita Panda

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By David Wild

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.